These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

29 related articles for article (PubMed ID: 25307006)

  • 1. Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey.
    Bertolini G; Rossi C; Anghileri A; Livigni S; Addis A; Poole D
    Intensive Care Med; 2007 Mar; 33(3):426-34. PubMed ID: 17325836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis.
    Vincent JL; O'Brien J; Wheeler A; Wittebole X; Garg R; Trzaskoma BL; Sundin DP
    Crit Care; 2006; 10(3):R74. PubMed ID: 16684364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current role of activated protein C therapy for severe sepsis and septic shock.
    Barie PS
    Curr Infect Dis Rep; 2008 Sep; 10(5):368-76. PubMed ID: 18687200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenecteplase for ST-elevation myocardial infarction in a patient treated with drotrecogin alfa (activated) for severe sepsis: a case report.
    Barra L; Shum J; Pickering JG; Kao R
    J Med Case Rep; 2009 Nov; 3():109. PubMed ID: 19946587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drotrecogin alfa (activated; Xigris): an effective and cost-efficient treatment for severe sepsis.
    Doig CJ; Zygun DA; Delaney A; Manns BJ
    Expert Rev Pharmacoecon Outcomes Res; 2004 Feb; 4(1):15-26. PubMed ID: 19807332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis.
    Annane D; Mira JP; Ware LB; Gordon AC; Hinds CJ; Christiani DC; Sevransky J; Barnes K; Buchman TG; Heagerty PJ; Balshaw R; Lesnikova N; de Nobrega K; Wellman HF; Neira M; Mancini ADJ; Walley KR; Russell JA
    Ann Intensive Care; 2018 Jan; 8(1):16. PubMed ID: 29388048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The protein C pathway: implications for the design of the RESPOND study.
    Vangerow B; Shorr AF; Wyncoll D; Janes J; Nelson DR; Reinhart K
    Crit Care; 2007; 11 Suppl 5(Suppl 5):S4. PubMed ID: 18269691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dream deferred: the rise and fall of recombinant activated protein C.
    Holder AL; Huang DT
    Crit Care; 2013 Mar; 17(2):309. PubMed ID: 23509922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sepsis-related acute kidney injury: a protective effect of drotrecogin alpha (activated) treatment?
    Janssen van Doorn K; Spapen H; Geers C; Diltoer M; Shabana W
    Acta Anaesthesiol Scand; 2008 Oct; 52(9):1259-64. PubMed ID: 18823466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Near-infrared spectroscopy StO2 monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock.
    Masip J; Mesquida J; Luengo C; Gili G; Gomà G; Ferrer R; Teboul JL; Payen D; Artigas A
    Ann Intensive Care; 2013 Sep; 3(1):30. PubMed ID: 24007807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose, off-label drotrecogin alfa (xigris) in severe sepsis.
    Wang S; Dabovic K; Spector RS
    P T; 2008 Aug; 33(8):469-76. PubMed ID: 19750177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why activated protein C was not successful in severe sepsis and septic shock: are we still tilting at windmills?
    Lai PS; Thompson BT
    Curr Infect Dis Rep; 2013 Oct; 15(5):407-12. PubMed ID: 23925482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drotrecogin alfa (activated) in clinical practice and current evidences.
    Büchele GL; Janiszewski M
    Rev Bras Ter Intensiva; 2008 Sep; 20(3):321-2. PubMed ID: 25307102
    [No Abstract]   [Full Text] [Related]  

  • 14. Drotrecogin alfa (activated) in clinical practice and current evidences: reply.
    Soares M; Machado FO; Torres VB; Salluh JI; Amaral AC
    Rev Bras Ter Intensiva; 2008 Sep; 20(3):323-4. PubMed ID: 25307103
    [No Abstract]   [Full Text] [Related]  

  • 15. Drotrecogin alfa activated in clinical practice and the current evidences.
    Soares M; Machado FO; Torres VB; Salluh JI; Amaral AC
    Rev Bras Ter Intensiva; 2008 Jun; 20(2):173-7. PubMed ID: 25307006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.
    Laterre PF; Macias WL; Janes J; Williams MD; Nelson DR; Girbes AR; Dhainaut JF; Abraham E
    Crit Care; 2008; 12(5):R117. PubMed ID: 18786266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.